CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies Ltd (CLGN) is named as issuer in a Rule 144 notice proposing the sale of 15,550 common shares for the account of Lillian S. Loewenbaum, identified as a 10% stockholder. The notice lists an aggregate market value of $58,934.00. Its remarks attribute 12,000 shares to The Loewenbaum Descendents U/A dated December 1, 1992, with George Walter Loewenbaum and Lillian Shaw Loewenbaum as trustees, and 3,550 shares to The Waterproof Partnership LTD, with them as partners.
CollPlant Biotechnologies Ltd. reported a total amount sold of $9,249,958 USD in an exempt offering of equity and ordinary warrants to purchase ordinary shares. The reported amount includes the exercise price of ordinary shares underlying the warrants at $3.74. The offering was made under Rule 506(b); the first sale was October 9, 2026, and total remaining to be sold was $0 USD.
The total offering amount excludes placement agent warrants. CollPlant says it intends to use net proceeds for general corporate purposes, including working capital and funding research and development programs. The sales-compensation section names H.C. Wainwright & Co., LLC and Rodman & Renshaw, LLC.
Ruty Ben Shlomi, a director of CollPlant Biotechnologies Ltd, reported direct holdings of 66,501 ordinary shares, 105,038 pre-funded warrants, and milestone pre-funded warrants covering up to 3,999,446 ordinary shares. Both warrant holdings list an exercise price of $0.0001. The reported security amounts were adjusted to reflect the 1-for-10 reverse stock split effective September 4, 2026; milestone warrant exercisability is subject to specified business milestones.
CollPlant Biotechnologies Ltd. (CLGN) closed a private placement on October 14, 2026, for 989,301 ordinary shares or pre-funded warrants in lieu, plus ordinary warrants to purchase up to 1,483,950 shares. Package prices were $3.74 per ordinary share with an accompanying warrant and $3.7499 per pre-funded warrant with an accompanying warrant. Gross proceeds are expected to be approximately $3.7 million before placement-agent fees and other expenses; net proceeds are intended for general corporate purposes, including working capital and research and development.
Ordinary warrants carry a $3.74 exercise price, are exercisable upon issuance, and expire five years after the effective date of a registration statement covering the underlying shares. CollPlant agreed to file a resale registration statement within 60 calendar days following October 9, 2026, and use best efforts to obtain effectiveness within 90 calendar days, or 120 calendar days if the SEC elects review. H.C. Wainwright & Co., LLC and Rodman & Renshaw LLC served as exclusive placement agents; they or their designees will receive warrants to purchase up to 59,358 shares at $4.675 per share.
CollPlant Biotechnologies Ltd. (CLGN) entered into definitive agreements for a private placement of 989,301 ordinary shares (or ordinary share equivalents in lieu thereof) and unregistered warrants to purchase up to 1,483,952 ordinary shares. The combined purchase price is $3.74 per ordinary share and accompanying warrants, or $3.7399 per ordinary share equivalent and accompanying warrants. Gross proceeds are expected to be approximately $3.7 million, before placement-agent fees and other related expenses payable by the company. Closing is expected on or about October 14, 2026, subject to customary closing conditions.
The warrants have a $3.74-per-share exercise price, are exercisable immediately upon issuance and expire five years after the effective date of a registration statement covering shares issuable upon exercise. CollPlant intends to use net proceeds primarily to accelerate LightSolver research and development on its laser-based supercomputing architecture and Laser Processing Unit technology, as well as for general corporate purposes including working capital. CollPlant also agreed to file a registration statement covering resale of the placement shares and shares underlying the warrants.
Ami Sagy reported beneficial ownership of 163,709 ordinary shares of CollPlant Biotechnologies Ltd. (CLGN), equal to 5.7% of the class. The reported position carries sole voting and sole dispositive power over 163,709 shares, with shared voting and shared dispositive power of 0. The percentage is based on the issuer-provided count of 2,866,715 ordinary shares outstanding as of September 30, 2026.
CollPlant Biotechnologies Ltd. reports that Ami Sagy, manager of the Sagy Group, beneficially owns 163,709 ordinary shares, or approximately 5.7% of the class. The reported percentage decreased because CollPlant issued ordinary shares since Amendment No. 4, filed November 28, 2025; Sagy says he did not acquire or dispose of shares since then and reported no transactions during the 60 days preceding this amendment. He has sole voting and dispositive power over the reported shares. The percentage uses 2,866,715 ordinary shares outstanding as of September 30, 2026, reflecting the issuer's 1-for-10 reverse share split effective September 4, 2026. Sagy states he is eligible to begin reporting on Schedule 13G under Rule 13d-1(c).
CollPlant Biotechnologies Ltd. announced that its subsidiary LightSolver filed a U.S. provisional patent application with the USPTO on October 6, 2026. Titled Configuring a Programmable Analog Processor to Solve Inhomogeneous Boundary Value Problems, it describes a method for using LightSolver’s all-optical, laser-based computing platform in scientific and engineering simulations.
The described approach incorporates boundary conditions and other problem parameters directly into computation. CollPlant says the method extends the simulations its platform can address, including problems modeled by partial differential equations associated with heat transfer, diffusion, electrostatics and fluid flow, including complex geometries and boundary conditions. LightSolver CEO and Co-Founder Dr. Ruti Ben-Shlomi said the application forms part of the subsidiary’s intellectual-property strategy and expands the problem space addressed by its Laser Processing Unit.
CollPlant Biotechnologies Ltd. reported first-half 2026 GAAP revenue of $181,000, versus $2.234 million in 2025, which included a $2.0 million milestone payment. Gross results were a $699,000 loss versus $1.86 million profit, and net loss was $5.823 million versus $4.799 million. Operating cash use was $5.382 million versus $3.607 million; cash was $2.559 million at June 30. Results exclude LightSolver, acquired September 3.
Agreed LightSolver consideration includes 336,103 ordinary shares, pre-funded warrants for 668,448 shares and milestone warrants for up to 22,231,164 shares. Milestone warrants depend on specified technological and commercial milestones; issuance of underlying shares is subject to a limit that may require shareholder approval. A September 30 amendment provides for converting LightSolver’s outstanding vested and unvested Section 3(i) options into CollPlant options. A 1-for-10 reverse split took effect September 4.
At the financial statements’ approval date, CollPlant said available liquidity was insufficient to fund operations and obligations for the following 12 months, creating substantial doubt about its ability to continue as a going concern. After June 30, it received the remaining $1.94 million gross proceeds from the June offering in July and approximately $5.2 million from warrant exercises in August and September.
CollPlant Biotechnologies Ltd. announced the publication of joint research by its subsidiary LightSolver Ltd. and the High-Performance Computing Center Stuttgart (HLRS). The peer-reviewed study compared an emulator of LightSolver’s Laser Processing Unit (LPU) architecture with established iterative algorithms running on a GPU to solve large-scale sparse systems of linear equations.
Across the benchmark problems evaluated, the study projected time-to-solution acceleration ranging from approximately 40× to more than 80,000×, depending on the algorithm and problem. The reported results are projections based on an emulator; the research describes potential uses for photonic processors as specialized accelerators for selected scientific and engineering workloads.